European CHMP recommends approval of licence extension of upadacitinib (Roinvoq)

The licence extension is for treatment of active psoriatic arthritis in adults who have responded inadequately to, or who are intolerant to one or more DMARDs and for treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.

Source:

European Medicines Agency